Fentanyl inhalation - Akela Pharma

Drug Profile

Fentanyl inhalation - Akela Pharma

Alternative Names: Fentanyl TAIFUN

Latest Information Update: 26 May 2015

Price : $50

At a glance

  • Originator LAB International
  • Developer Akela Pharma; Teikoku Seiyaku
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Aug 2011 Teikoku Seiyaku terminates its licensing agreement with Akela Pharma for fentanyl inhalation in Japan
  • 09 Aug 2011 Discontinued - Phase-III for Cancer pain in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top